What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

UroGen Pharma Announces Positive Clinical Trial Results for Bladder Cancer Treatment ZUSDURI

UroGen Pharma Ltd. (URGN) has announced positive clinical data from its pivotal ENVISION trial for ZUSDURI™ (UGN-102). The drug achieved durable complete responses in patients suffering from recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC). According to the report, the results demonstrated significant efficacy across various risk groups as classified by the EORTC. The company plans to present a detailed recurrence score analysis at the upcoming ASCO-GU 2026 symposium. These findings support ZUSDURI’s potential as a primary treatment option, marking a significant regulatory milestone for the company. Investors view this development as a major catalyst for UroGen's oncology pipeline and future commercial prospects.

UroGen Pharma Announces Positive Clinical Trial Results for Bladder Cancer Treatment ZUSDURI

Key Facts

Social Buzz

Instruments